3.1. Trial Participants
overweight, weight loss
ADVERSE EVENTS, MAY, OBESE
From May 2021 to May 2022, 243 women were assessed for eligibility. Among them, 175 were excluded considering inclusion/exclusion criteria or other reasons (106 women did not match the criteria for inclusion, 16 women declined to participate, and 53 women were excluded for other reasons). A total of 68 overweight or obese PCOS-affected participants were randomly assigned to the following groups: 35 participants to the dulaglutide + CRD group and 33 participants to the CRD group. Among the total number of women who underwent randomization, 27 women in the dulaglutide + CRD group and 23 women in the CRD group completed a 7% weight loss goal of initial body weight within 6 months. Additionally, 4 women failed to obtain the predefined weight loss within the allowed 6-month period and 14 women were lost to follow-up (2 women for unwillingness to continue for adverse events, 3 women for automatically quitting, and 9 women for diet protocol violation) (